Patents by Inventor Patrick MAVINGUI

Patrick MAVINGUI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vaccine compositions comprising an attenuated mutant Zika virus
    Patent number: 10849943
    Abstract: The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: December 1, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LA REUNION SAINT DENIS, INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS
    Inventors: Philippe Despres, Gilles Gadea, Patrick Mavingui, Wildriss Viranaicken
  • VACCINE COMPOSITIONS COMPRISING AN ATTENUATED MUTANT ZIKA VIRUS
    Publication number: 20190255125
    Abstract: The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.
    Type: Application
    Filed: June 22, 2017
    Publication date: August 22, 2019
    Inventors: Philippe DESPRES, Gilles GADEA, Patrick MAVINGUI, Wildriss VIRANAICKEN